Farewell, punks, page-8

Dazuu, My calculations suggest the infusions business is worth very little. The GPM appears less than 50% and, given sales staff and admin support costs, it's likely marginally profitable. Lucky if it is worth a small fraction of your estimated low end. On a revenue multiple, the ADAPT business (not TAVR) could be worth between $30m to $40 million. However, the company does not appear willing to sell (perhaps, no buyer) but seems intent on playing chicken with receivership prospects.  An imminent TAVR licensing deal is really shareholders' only saviour.